Evidence map›Paper›PMID 40939150›Full record

Trial reportClinical pharmacology in drug development2025

Safety, Tolerability, and Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, in Healthy Chinese Participants.

Jingjing Wang, Nanyang Li, Jinjie He, Jing Zhang, Lili Wang, William Kielbasa, Chenxi Qian, Yanjie Zhang, Liang Wang

Abstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical pharmacology in drug development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jingjing WangClinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Nanyang LiClinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Jinjie HeClinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Jing ZhangClinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
Lili WangClinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
William KielbasaEli Lilly and Company, Indianapolis, IN, USA.
Chenxi QianEli Lilly and Company, Shanghai, China.
Yanjie ZhangEli Lilly and Company, Shanghai, China.
Liang WangDeparment of Neurology, Huashan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Galcanezumab is used in several regions, including the United States, Europe, and China, as a preventive treatment for migraine. This study aimed to evaluate the safety, tolerability, and pharmacokinetics (PK) of galcanezumab in healthy Chinese participants. In this phase I single-dose study, 30 healthy adults were assigned to one of the two cohorts (120 or 240 mg) and randomized in a 4:1 ratio to receive a single subcutaneous (SC) dose of galcanezumab or placebo. Overall, 29 (96.7%) participants reported 93 treatment-emergent adverse events (TEAEs), with 21 participants reporting 44 TEAEs related to the study treatment. Most study-related TEAEs (95%) were mild in severity. The most commonly reported TEAE was upper respiratory tract infection. The PK data demonstrated that maximum observed drug concentration (C

Indexed as

Antibodies, Monoclonal, HumanizedCalcitonin Gene-Related PeptideAdultArea Under CurveChinaDose-Response Relationship, DrugDouble-Blind MethodEast Asian PeopleFemaleHalf-LifeHealthy VolunteersHumansInjections, SubcutaneousMaleMiddle AgedMigraine DisordersAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related PeptidegalcanezumabChinesegalcanezumabmigrainepharmacokineticsphase Isafety

Identifiers

PMID40939150
PMCPMC12672407

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.